There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on aTyr Pharma (LIFE – Research Report), Apellis Pharmaceuticals (APLS – Research Report) and Harpoon Therapeutics (HARP – Research Report) with bullish sentiments.
aTyr Pharma (LIFE)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on aTyr Pharma today and set a price target of $35.00. The company’s shares closed last Wednesday at $1.64, close to its 52-week low of $1.56.
According to TipRanks.com, Pantginis has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on aTyr Pharma is a Strong Buy with an average price target of $21.50, representing a 1203.0% upside. In a report issued on September 12, JonesTrading also reiterated a Buy rating on the stock with a $12.00 price target.
See today’s best-performing stocks on TipRanks >>
Apellis Pharmaceuticals (APLS)
H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Apellis Pharmaceuticals today and set a price target of $82.00. The company’s shares closed last Wednesday at $42.51.
According to TipRanks.com, Tsao is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Apellis Pharmaceuticals with a $70.00 average price target.
Harpoon Therapeutics (HARP)
In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Harpoon Therapeutics, with a price target of $7.50. The company’s shares closed last Wednesday at $6.54, close to its 52-week low of $5.44.
According to TipRanks.com, Ramakanth is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Harpoon Therapeutics is a Moderate Buy with an average price target of $34.17.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LIFE:
- aTyr Pharma presents efzofitimod data
- aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
- aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- aTyr Pharma reports Q2 EPS (22c), consensus (28c)
- aTyr Pharma price target raised to $20 from $13 at Piper Sandler
